2型糖尿病短期胰岛素强化治疗临床专家指导意见

2017-06-30 中国内分泌相关专家小组(统称) 药品评价.2017,14(9):5-13.

胰岛素强化治疗是强化血糖控制的重要方法之一。临床上,伴有明显的高血糖症状的新诊断2型糖尿病(type 2 diabetes,T2DM)患者,或者已诊断为T2DM、使用两种或两种以上口服降糖药联合治疗3个月以上血糖仍明显升高[糖化血红蛋白(hemoglobin A1c,HbA1c)>9.0%],以及已经起始胰岛素治疗且经过充分的剂量调整血糖仍未达标(HbA1c>7.0%)的T2DM患者,往往需要进行

中文标题:

2型糖尿病短期胰岛素强化治疗临床专家指导意见

发布日期:

2017-06-30

简要介绍:

胰岛素强化治疗是强化血糖控制的重要方法之一。临床上,伴有明显的高血糖症状的新诊断2型糖尿病(type 2 diabetes,T2DM)患者,或者已诊断为T2DM、使用两种或两种以上口服降糖药联合治疗3个月以上血糖仍明显升高[糖化血红蛋白(hemoglobin A1c,HbA1c)>9.0%],以及已经起始胰岛素治疗且经过充分的剂量调整血糖仍未达标(HbA1c>7.0%)的T2DM患者,往往需要进行短期的胰岛素强化治疗以短时间内改善高糖毒性。然而,对短期胰岛素强化治疗的具体指征、治疗方案的选择、胰岛素剂量调整方法,以及强化治疗之后的后续治疗方案如何选择等仍缺乏具体指导。因此,中国内分泌学专家基于现有的证据和临床经验,制订了《2型糖尿病短期胰岛素强化治疗临床专家指导意见》。

 

拓展指南:糖尿病相关指南:

相关资料下载:
[AttachmentFileName(sort=100, fileName=2型糖尿病短期胰岛素强化治疗临床专家指导意见)] GetToolGuiderByIdResponse(projectId=1, id=ae3cf1c001a88e87, title=2型糖尿病短期胰岛素强化治疗临床专家指导意见, enTitle=, guiderFrom=药品评价.2017,14(9):5-13., authorId=null, author=, summary=胰岛素强化治疗是强化血糖控制的重要方法之一。临床上,伴有明显的高血糖症状的新诊断2型糖尿病(type 2 diabetes,T2DM)患者,或者已诊断为T2DM、使用两种或两种以上口服降糖药联合治疗3个月以上血糖仍明显升高[糖化血红蛋白(hemoglobin A1c,HbA1c)>9.0%],以及已经起始胰岛素治疗且经过充分的剂量调整血糖仍未达标(HbA1c>7.0%)的T2DM患者,往往需要进行, cover=, journalId=null, articlesId=null, associationId=666, associationName=中国内分泌相关专家小组(统称), associationIntro=这是一个统称,其下指南和专家共识均由国内内分泌领域的专家制定。, copyright=0, guiderPublishedTime=Fri Jun 30 00:00:00 CST 2017, originalUrl=, linkOutUrl=, content=<P>胰岛素强化治疗是强化血糖控制的重要方法之一。临床上,伴有明显的高血糖症状的新诊断2型糖尿病(type 2 diabetes,T2DM)患者,或者已诊断为T2DM、使用两种或两种以上口服降糖药联合治疗3个月以上血糖仍明显升高[糖化血红蛋白(hemoglobin A1c,HbA1c)>9.0%],以及已经起始胰岛素治疗且经过充分的剂量调整血糖仍未达标(HbA1c>7.0%)的T2DM患者,往往需要进行短期的胰岛素强化治疗以短时间内改善高糖毒性。然而,对短期胰岛素强化治疗的具体指征、治疗方案的选择、胰岛素剂量调整方法,以及强化治疗之后的后续治疗方案如何选择等仍缺乏具体指导。因此,中国内分泌学专家基于现有的证据和临床经验,制订了《2型糖尿病短期胰岛素强化治疗临床专家指导意见》。 </P> <P> </P>拓展指南:<strong>与<font color=red>糖尿病</font>相关指南:</strong><br><ul><li><a href="http://www.medsci.cn/guideline/show_article.do?id=1bfd11c001a865dd" title="儿童青少年2型糖尿病诊治中国专家共识" target=_blank>儿童青少年2型糖尿病诊治中国专家共识</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=989af1c001a855e9" title="2017 SED/SERV共识指南:糖尿病视网膜病变的诊断和治疗(更新版)" target=_blank>2017 SED/SERV共识指南:糖尿病视网膜病变的诊断和治疗(更新版)</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=9807c1c001a83ea5" title="中国糖尿病药物注射技术指南(2016年版)" target=_blank>中国糖尿病药物注射技术指南(2016年版)</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=20bf51c001ae2321" title="2016共识声明:患有糖尿病和慢性肾病患者应用抗糖尿病药物的剂量调整" target=_blank>2016共识声明:患有糖尿病和慢性肾病患者应用抗糖尿病药物的剂量调整</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=07fcf1c001a668d7" title="2型糖尿病合并动脉粥样硬化性心血管疾病患者降糖药物应用专家共识" target=_blank>2型糖尿病合并动脉粥样硬化性心血管疾病患者降糖药物应用专家共识</a></li> 更多信息请点击:<a href="http://www.medsci.cn/guideline/list.do?q=%E7%B3%96%E5%B0%BF%E7%97%85" target=_blank>有关糖尿病更多指南</a></ul>, tagList=[TagDto(tagId=2052, tagName=2型糖尿病), TagDto(tagId=57556, tagName=短期胰岛素强化治疗)], categoryList=[CategoryDto(categoryId=6, categoryName=内分泌科, tenant=100), CategoryDto(categoryId=8, categoryName=糖尿病, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=其他, guiderLanguage=1, guiderRegion=3, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=7879, appHits=852, showAppHits=0, pcHits=4499, showPcHits=3047, likes=171, shares=34, comments=3, approvalStatus=1, publishedTime=Sun Aug 27 21:07:35 CST 2017, publishedTimeString=2017-06-30, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Sun Aug 27 21:07:35 CST 2017, updatedBy=null, updatedName=null, updatedTime=Sat Jan 06 15:33:13 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2型糖尿病短期胰岛素强化治疗临床专家指导意见)])
2型糖尿病短期胰岛素强化治疗临床专家指导意见
下载请点击:
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=967259, encodeId=e0a896e2591c, content=非常有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02972000979, createdName=walking, createdTime=Thu May 20 16:16:05 CST 2021, time=2021-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=244553, encodeId=910f24455346, content=学习了.谢谢., beContent=null, objectType=guider, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Sat Sep 16 08:54:31 CST 2017, time=2017-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=241489, encodeId=14db2414894f, content=学习了.谢谢., beContent=null, objectType=guider, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Thu Sep 07 18:22:27 CST 2017, time=2017-09-07, status=1, ipAttribution=)]
    2021-05-20 walking

    非常有用

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=967259, encodeId=e0a896e2591c, content=非常有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02972000979, createdName=walking, createdTime=Thu May 20 16:16:05 CST 2021, time=2021-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=244553, encodeId=910f24455346, content=学习了.谢谢., beContent=null, objectType=guider, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Sat Sep 16 08:54:31 CST 2017, time=2017-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=241489, encodeId=14db2414894f, content=学习了.谢谢., beContent=null, objectType=guider, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Thu Sep 07 18:22:27 CST 2017, time=2017-09-07, status=1, ipAttribution=)]
    2017-09-16 惠映实验室

    学习了.谢谢.

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=967259, encodeId=e0a896e2591c, content=非常有用, beContent=null, objectType=guider, channel=null, level=null, likeNumber=66, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=02972000979, createdName=walking, createdTime=Thu May 20 16:16:05 CST 2021, time=2021-05-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=244553, encodeId=910f24455346, content=学习了.谢谢., beContent=null, objectType=guider, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Sat Sep 16 08:54:31 CST 2017, time=2017-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=241489, encodeId=14db2414894f, content=学习了.谢谢., beContent=null, objectType=guider, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/xkvRjYnJzzRJ2R0y7VhicibvkjPWHjIMmu4ZpKnE9cWAu4lVicS3uDUCfF4M4JWvrkrYfpb2KehPV0Ee29tPqyPEebBUibiaKhnvD/0, createdBy=f8412001184, createdName=惠映实验室, createdTime=Thu Sep 07 18:22:27 CST 2017, time=2017-09-07, status=1, ipAttribution=)]
    2017-09-07 惠映实验室

    学习了.谢谢.

    0